Pre-Activation of Toll-Like Receptor 2 Enhances CD8+ T-Cell Responses and Accelerates Hepatitis B Virus Clearance in the Mouse Models

Yong Lin1,2,3†, Xuan Huang2,4†, Jun Wu3, Jia Liu2,3, Mingfa Chen3, Zhiyong Ma2, Ejuan Zhang5, Yan Liu1, Shunmei Huang3, Qian Li5, Xiaoyong Zhang4, Jinlin Hou4, Dongliang Yang3, Mengji Lu1,2* and Yang Xu1*

1 Department of Microbiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Institute of Virology, University Hospital of Essen, Essen, Germany, 3 Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 4 State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China, 5 Mucosal Immunity Research Group, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

Toll-like receptors (TLRs) play a crucial role in activation of innate immunity, which is essential for inducing effective adaptive immune responses. Our previous studies have shown that toll-like receptor 2 (TLR2) is required to induce effective virus-specific T-cell responses against hepatitis B virus (HBV) in vivo. However, the contribution of TLR2 activation to adaptive immunity and HBV clearance remains to be clarified. In this study, we explored the hydrodynamic injection (HI) mouse models for HBV infection and examined how the TLR2 agonist Pam3CSK (P3C) influences HBV control and modulates HBV-specific T-cell response if applied in vivo. We found that TLR2 activation by P3C injection leads to the rapid but transient production of serum proinflammatory factors interleukin-6 and tumor necrosis factor-α and activation of CD8+ T cells in vivo. Then, the anti-HBV effect and HBV-specific T-cell immunity were investigated by TLR2 activation in the mouse models for persistent or acute HBV infections using HBV plasmids pAAV-HBV1.2 and pSM2, respectively. Both P3C application at early stage and pre-activation promoted HBV clearance, while only TLR2 pre-activation enhanced HBV-specific T-cell response in the liver. In the mouse model for acute HBV infection, P3C application had no significant effect on HBV clearance though P3C significantly enhanced the HBV-specific T-cell response. Collectively, TLR2 pre-activation enhances HBV-specific T-cell responses and accelerates HBV clearance in HI mouse models. Thus, the modulation of host immune status by TLR2 agonists may be explored for immunotherapeutic strategies to control HBV infection.

Keywords: toll-like receptor 2, hepatitis B virus, mouse model, proinflammatory cytokines, T-cell immunity

Abbreviations: CHB, chronic hepatitis B; HBV, hepatitis B virus; HBsAg, Hepatitis B surface antigen; HBeAg, Hepatitis B e antigen; IFN-γ, interferon gamma; IL-6, interleukin-6; TLR2, toll-like receptor 2; PAMPs, pathogen-associated molecular patterns; PBMCs, peripheral blood mononuclear cells; PMA, phorbol-12-myristate-13-acetate; PRRs, pattern recognition receptors; TGF-β, transforming growth factor-beta; TNF-α, tumor necrosis factor-α.
INTRODUCTION

Hepatitis B virus (HBV) is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma (1, 2). The robust, polyclonal, and multispecific CD4+ and CD8+ T-cell response and neutralizing antibody responses contribute to the resolution of HBV infection. CD8+ T cells kill infected cells and secrete antiviral cytokines [mainly interferon gamma (IFN-γ)] that inhibit HBV replication non-cytopathically (3, 4). Neutralizing antibodies limit viral spread from residual productively infected hepatocytes (5).

Hepatitis B virus was at one time considered to be a “stealth virus” that induces negligible innate immune responses during the early phase of infection (6). Gene array analysis failed to detect an induction of host innate immunity during acute HBV infection in chimpanzees, as compared with HCV infection (7). A recent study in cell culture and a transplant mouse model also showed that HBV did not induce interferon (IFN) responses in hepatocytes but cytokine production in macrophages (8). However, there is accumulating evidence that the innate branch of the host immune system plays an important role in the control of HBV infection (9–11). Pattern recognition receptors, including toll-like receptors (TLRs), NOD-like receptors, RIG-I-like receptors, and leucine-rich repeat-containing receptors (NLRs), are essential for sensing invading pathogens, initiating innate immune responses, limiting the spread of infection, and orchestrating the activation and development of the adaptive immune response (12).

Among the PPRs, toll-like receptor 2 (TLR2) is widely expressed by antigen-presenting cells, endothelial and epithelial cells, and lymphocyte subsets, including activated and memory T cells (13, 14). TLR2 is a receptor for microbial pathogen-associated molecular patterns (PAMPs) like lipoproteins (12). TLR2 recognizes microbial PAMPs in its homodimeric form or alternatively as a heterodimer with TLR1 or 6 forms and activates various intracellular signaling molecules and transcription factors. PAMPs can bind to TLR2 receptor, which leads to cellular stimulation leads to activation of cellular pathways including toll-like receptors (TLRs), NOD-like receptors, RIG-I-like receptors, and leucine-rich repeat-containing receptors (NLRs), which are essential for sensing invading pathogens, initiating innate immune responses, limiting the spread of infection, and orchestrating the activation and development of the adaptive immune response (12).

As TLR activation plays an important role for HBV control, it is attempted to explore TLR ligands for immunomodulation and treatment of chronic HBV infection (10, 23). Wu et al. applied poly(I:C), a TLR3 ligand, to mice with persistent HBV replication and found that poly(I:C) could stimulate immune responses in the mouse liver in an IFN-dependent manner and led to HBV clearance by recruiting HBV-specific T cells into the liver (24). Recently, Huang et al. showed that TLR9 ligand can induce recruitment of immune cells into the liver and formation of immune-related structures called intrahepatic myeloid cell aggregates for T-cell population expansion (iMATEs), which may support the local immune control of infections (25). Thus, we questioned whether and how TLR2 activation may promote specific immune responses to HBV proteins and contribute to HBV control. In the present study, we examined the immune activation by application of a potent TLR2 ligand and a synthetic lipopeptide-Pam3CSK4-in mice and how the immune activation promotes HBV control in the mouse models for chronic and acute HBV infections.

MATERIALS AND METHODS

Mice

Male C57BL/6 mice aged 6–8 weeks were purchased from Beijing HFK Bioscience Co. Ltd (China) and were maintained under specific pathogen-free conditions in the Experimental Animal Center of Tongji Medical College, Huazhong University of Science and Technology. Animals were treated according to the Guidelines of the National Institutes of Health for Animal Care and Use.

Plasmid and Peptides

Plasmid pAAV/HBV1.2 (kindly provided by Prof. Chen PJ, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taiwan) contains a terminally redundant 1.2x copy of genotype A HBV genome (26). Plasmid pSM2 (provided by Dr. Hans Will, Heinrich-Pette-Institute, Hamburg, Germany) is a replication-competent HBV clone harboring a head-to-tail tandem dimeric HBV genome (GenBank accession number: V01460). Both vectors were previously used by our group (24, 27).

The peptide of Kb-restricted HBV Cor93–100 epitope (MGLKFRQL) was synthesized and purchased from Chinese Peptide Company (Hangzhou, China). The synthetic lipopeptide Pam3CSK4 (P3C, TLR2/TLR1 ligand) was purchased from EMC Microcollections (Tübingen, Germany).

Hydrodynamic Injection

Briefly, 10 µg of plasmid DNA (pAAV/HBV1.2 or pSM2) was hydrodynamically injected into the tail vein of C57BL/6 mice in
a volume of phosphate-buffered saline (PBS) solution equivalent to 10% body weight within 5–8 s (24, 26, 27).

**Analysis of HBV Serological Markers and HBV DNA**

Serum samples were collected from mice at the indicated time points after HI and diluted 1:10 with Duluent Universal (Roche Diagnostics, Switzerland). The levels of serum HBsAg, Hepatitis B e antigen (HBeAg), anti-HBc, anti-HBs, and HBV DNA were determined as described previously (24). Nucleocapsid HBV DNA was extracted from 60 mg mouse liver tissue according to the protocols published previously (28). The levels of HBV DNA were determined by SYBR Green Real-time PCR Master Mix (ToyoBo, Japan). The following primers were used: forward primer, 5'-CTGCATCTGCCTGCTATG-3' (nt 408–425) and reverse primer, 5'-CACACTGAAC/AAATGGCAC-3' (nt 685–701), based on the reference sequence with GenBank accession number AY220698.1.

**Detection of Cytokine Production by ELISA**

Serum samples were collected from mice at the indicated time points after injection of P3C or PBS. The levels of serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by specific Mouse cytokine ELISA kits (eBioscience, CA) according to the manufacturer's instructions. Splenocytes were isolated from mice and cultured with 0.002% DNAase I (Sigma-Aldrich), and 10% fetal bovine serum solution containing 0.05% collagenase type II (Sigma-Aldrich), and then used to stain mouse lymphocytes according to the technical instructions (27). The cells were first incubated with anti-CD16/CD32 rat anti-mouse antibody (BD Pharmingen) and then stained with anti-CD8 and 7AAD. After washing, the cells were incubated with dimer for 1 h, followed by staining with anti-IgG1 antibody (eBioscience) for 30 min at 4°C. Finally, stained cells were detected on FACS Calibur (BD Biosciences) and analyzed by using FlowJo software (Tree Star, OR).

**Statistical Analysis**

Statistical analyses were performed using GraphPad Prism software version 5 (GraphPad Software Inc., CA, USA). Data were analyzed using nonparametric one-way ANOVA and Dunn's multiple comparison test or Student's t-test. P-values < 0.05 were considered significant.

**RESULTS**

**TLR2 Activation by P3C Application Leads to the Production of Pro-Inflammatory Factors In Vivo in the Presence of HBV Replication**

First, we examined the immune activation in vivo by application of TLR2 ligands P3C in C57BL/6 mice without and with HBV replication. C57BL/6 mice were treated with 50 and 100 µg of P3C by subcutaneous (SC) injection or PBS as control, respectively. The serum level of IL-6 and TNF-α was detected by specific ELISA at the indicated time points. The production of IL-6 and TNF-α was transient after P3C injection, with the levels peaking at 3 h, in a dose-dependent manner, and disappearing at 12 h after injection (Figure 1A). The plasmid pAAV-HBV1.2 was first hydrodynamically injected into C57BL/6 mouse to establish HBV replication (see below); then, 50 µg of P3C or PBS were subcutaneously injected at day 4 post-HI. The kinetic of the serum IL-6 and TNF-α production in mice with HBV replication had the same pattern like that in naive mice. Thus, the presence
of HBV replication did not generally affect the production of pro-inflammatory cytokines IL6 and TNF-α stimulated by P3C (Figure 1B).

**Activation of TLR2 by P3C at Early Stage Inhibits HBV Replication in HBV-Persistent Replicating Mice**

Next, we tested whether application of TLR2 ligand P3C would inhibit HBV replication in the HBV mouse model based on HI of pAAV-HBV1.2. In this model, HBV could replicate for a prolonged time in vivo (26). C57BL/6 mice were SC treated with 50 µg of P3C or PBS three times at days 0, 7, and 14 after HI of pAAV-HBV1.2 (D0 group). The kinetics of serum HBsAg, HBeAg, and HBV DNA indicated that the early P3C treatment at days 0, 7, and 14 inhibited HBV replication in mice (Figures 2A,B). While all mice treated with PBS remained positive for HBV infection markers, these markers gradually became negative in some individual animals. At day 77 after HI, serum HBsAg and HBeAg were undetectable in P3C treated mice, while serum HBsAg was kept at low concentrations (≤800 cut-off index, COI) in 37.5% of mice. Consistently, HBV DNA in mouse liver tissue samples was reduced by P3C treatment and was below the detection limit of the real-time PCR assay at day 77 (Figure 2C). The number of HBcAg- and HBsAg-positive hepatocytes in the mouse liver sections was detected by immunohistochemical staining and significantly decreased by P3C treatment as compared with PBS control (Figure 2D; Figure S1A in Supplementary Material). Anti-HBs antibody was positively tested in two P3C-treated mice at day 77, accompanied by the disappearance of serum HBsAg (Figure 2E). These results indicated that HBV could be cleared from some mice by P3C treatment in this model.

However, the frequencies and functionality of HBV-specific CD8+ T cells in the liver and spleen were not increased by P3C treatment at days 0, 7, and 14 (Figures 2F,G; Figures S1B,C in Supplementary Material), according to the results of staining with peptide Cor93-100-loaded dimers and intracellular cytokine staining. The cytokine production in the mouse liver was determined by real-time RT-PCR at day 4, 10, 21, and 77 after the first P3C application. The mRNA levels of IFN-β, proinflammatory cytokines IL-6 and TNF-α, and anti-inflammatory cytokine IL-10 were slightly higher than the control at day 4 (Figure 2H). It is not conclusive, which immune-related factor was responsible for HBV clearance.

Besides, C57BL/6 mice were SC treated with 50 µg of P3C three times at days 14, 21, and 28 after HI (D14 group). The kinetics of serum HBsAg, HBeAg, and HBV DNA indicated that P3C treatment at the late time points had no effect on HBV replication in mice (Figures 3A,B). We found that 2 of 7 mice of the treated group spontaneously lost HBsAg and showed seroconversion to anti-HBs positive but with low anti-HBs antibody titers <20 IU/L. At the same time, one mouse of the control showed HBsAg seroconversion (Figure 3C). No statistical significance was found for HBsAg seroconversion and anti-HBs titers between the mouse groups.

Taken together, TLR2 activation at early time points after HBV HI inhibited HBV replication, likely by inducing the production of inflammatory cytokines, but not at late time points. Interestingly, the reduction and clearance of HBV replication was a relatively slow process, spanning over more than 10 weeks.

**Pre-Activation of TLR2 Accelerates HBV Clearance and Promotes HBV-Specific T-Cell Response in the Liver in the Mouse Model of Persistent HBV Replication**

Our previous study with poly(I:C), a TLR3 ligand, demonstrated that direct application of TLR ligands into the liver may effectively recruit specific T cells and control HBV replication (24). Thus, we questioned whether TLR2 activation by intrahepatic application of P3C may enhance immune control of HBV infection.

First, we treated C57BL/6 mice with 20 µg of P3C or PBS by intravenous (IV) injection. Liver NPCs and splenocytes were separated at day 7 after IV. The frequencies of CD4+, CD8+, CD11b+, CD11c+, and F4/80+ cells in the liver were analyzed by flow cytometry. We observed that the frequency of resident F4/80+ Kupffer cells in the liver was decreased. In contrast, the frequency of CD11c+ cells (DC) in the liver was slightly increased by P3C injection. However, the frequencies of CD4+ and CD8+ T cells in the liver and spleen were unchanged (Figure 4A). We further analyzed the expression of the activation markers of CD25, CD43, and CD100 on CD8+ T cells by flow cytometry. The results showed increased expression of these surface markers on CD8+ cells in the liver and spleen, indicating that P3C application led to a general immune stimulation and CD8+ T-cell...
FIGURE 2 | Continued
FIGURE 3 | Application of toll-like receptor 2 ligand P3C at a late time point after hydrodynamic injection (HI) does not inhibit hepatitis B virus (HBV) replication in the model for persistent HBV replication. C57BL/6 mice received (HI) with plasmid pAAV-HBV1.2. These mice were then treated three times with 50 µg of P3C or phosphate-buffered saline administered by subcutaneous (SC) injection at day 0, 7, and 14 (therefore, designated as group D0). (A) Serological markers of HBV infection HBsAg, Hepatitis B e antigen (HBeAg), and HBV DNA were assayed at the indicated time points by ECLIA (Roche). The cut-off value of the HBsAg and HBeAg assays was set at cut-off index (COI) of 1.0. The cut-off value of the HBV DNA real-time PCR was $4.0 \times 10^4$ copies/ml. (B) Positivity for HBsAg or HBeAg was defined as ≥1. (C) Liver tissue sections were stained with anti-HBc antibodies (magnification, 200×). The number of HBcAg positive hepatocytes was counted. (D) Liver tissues were collected from the mouse liver at day 4, 10, 21, and 77 after HI. (E) The specific CD8+ T cells against HBcAg Cor93–100 epitope were detected by Cor93–100 peptide-loaded dimer staining. (F) Liver tissue sections were stained with anti-HBc antibodies (magnification, 200×). The number of HBcAg positive hepatocytes was counted. (G) The serum levels of anti-HBs and anti-HBc antibodies were detected at the indicated time points by ECLIA. The cut-off value of anti-HBs antibody assay was 10 IU/L. The cut-off value of anti-HBc antibody assay was 1.0 COI (<1.0 COI indicates a positive reaction). (H) Liver tissues were collected from the mouse liver at day 4, 10, 21, and 77 after HI. The mRNA expression levels of cytokines in the liver were determined by real-time RT-PCR. Beta-actin was used as an internal reference. Eight mice were analyzed per group, and the experiments were repeated at least once. Data were analyzed using an unpaired Student’s t test. Statistically significant differences between the groups are indicated as *P < 0.05 and **P < 0.01.
experiment (Figures 2A,B). By pretreatment with P3C, serum HBsAg and HBeAg were cleared in 4 of 5 mice at day 35 after HI, along with decrease of serum HBV DNA below the detection limit (Figures 5A,B). Most importantly, anti-HBs antibody became positive in all P3C pre-treated mice at day 35 (Figure 5C). These results demonstrated that the P3C pre-treatment strongly promoted HBV clearance in mice that usually established persistent HBV replication. At day 35 after HI, lymphocytes were prepared from the liver and spleen and stimulated with HBcAg peptide ex vivo. The IHLs produced higher levels of IFN-γ (Figure 5D). Intracellular cytokine staining demonstrated that the frequencies of intrahepatic IFN-γ-producing CD8+ T cells were increased in response to ex vivo stimulation, while the fractions producing TNF-α and IL-2 did not change in a significant way (Figure 5E; Figure S2 in Supplementary Material). Collectively, the single injection of P3C at day 14 before HBV HI potently enhanced HBV-specific CD8+ T-cell response and led to rapid and efficient HBV clearance in the mouse model of persistent HBV replication.

**TLR2 Activation Enhances HBV-Specific T-Cell Response but Does Not Change the Kinetics of HBV Clearance in the Mouse Model of HBV Acute Infection**

As pre-activation of TLR2 by P3C administration resulted in an accelerated HBV clearance in the mouse model for chronic HBV infection, we were interested to examine whether TLR2 pre-activation may also change the kinetics of HBV clearance in the mouse model for acute HBV infection. C57BL/6 mice were administered with 20 µg of P3C or PBS by IV injection at day 14 (D-14) before HI of plasmid pSM2. Again, the serum HBsAg, HBeAg, and HBV DNA disappeared in mice at day 21 after HI (Figures 6A,B), indicating that P3C treatment did not accelerate HBV clearance in mice. Similar to the previous experiments, P3C treatment significantly increased the frequencies of HBV-specific CD8+ T cells from P3C-treated mice were also better in IFN-γ, TNF-α, and IL-2 production (Figure 6D). In conclusion, TLR2 activation
Pre-treatment with P3C accelerates hepatitis B virus (HBV) clearance in the mouse model for persistent HBV replication and promotes intrahepatic HBV-specific T-cell response. C57BL/6 mice were pretreated once with 20 µg of P3C or phosphate-buffered saline administered by intravenous (IV) injection at day 14 (D-14) before hydrodynamic injection (HI) with plasmid pAAV-HBV1.2. (A) Serological markers of HBV infection HBsAg, Hepatitis B e antigen (HBeAg), and HBV DNA were assayed at the indicated time points. (B) Positivity for HBsAg or HBeAg was defined as ≥1*. (C) The serum levels of anti-HBs and anti-HBc antibodies were detected at the indicated time points. (D,E) Lymphocytes were isolated from the mouse liver and spleen at day 35 after HI. (D) The lymphocytes were stimulated with peptide Cor93–100 for 48 h. Interferon gamma (IFN-γ) production was measured by ELISA. (E) The functionality of intrahepatic HBV-specific CD8+ T cells was determined by intracellular cytokine staining after ex vivo stimulation with peptide Cor93–100 for 5 h. The percentage of HBV-specific IFN-γ+ of CD8+ T cells was detected by flow cytometry. Five mice were analyzed per group, and the experiments were repeated at least once. Data were analyzed using an unpaired Student’s t test. Statistically significant differences between the groups are indicated as *P < 0.05 and **P < 0.01.

by P3C promotes the HBV-specific T-cell response but does not show an effect on HBV clearance in the mouse model for acute HBV infection.

**DISCUSSION**

In the present study, we investigated how TLR2 activation contributes to the control of HBV infection and immune response in the HBV HI mouse models. Our results have shown that pre-activation of TLR2 accelerates HBV clearance and promotes intrahepatic HBV-specific T-cell response in the chronic HBV mouse model (Figure 7). In the model for chronic HBV infection, early TLR2 activation led to viral suppression but without enhancing intrahepatic HBV-specific T-cell response, while no antiviral effect was observed if TLR activation occurred at a later time point.

Previously, we examined the role of TLR2 in HBV control and clearance in TLR2-deficient mouse model (20). Our data showed that lack of TLR2 expression led to elevated HBV replication and gene expression but did not delay HBV clearance. TLR2 deficiency resulted in impaired specific CD8+ T cell responses. However, HBV-specific CD8+ T cells were still recruited into the liver in a high level and produced IFN-γ that is required for HBV clearance (20). This work demonstrated the requirement of TLR2 for HBV control and clearance but did not indicate whether and how targeted TLR2 activation by ligands may promote host immune responses to HBV and HBV control. The present study gives answers to these remaining questions.

Our previous studies and those of other research groups showed that TLR2 activation in human hepatoma cells and primary woodchuck hepatocytes leads to reduction of HBV and WHV replication in vitro (16, 17). Activation of TLR2 signaling leads to transient production of pro-inflammatory cytokines that act directly as antiviral mediators, albeit with limited effect and may contribute to anti-HBV effect (17). However, this direct antiviral effect was rather weak as it did not lead the rapid HBV clearance in the chronic HBV mouse models (Figure 2) (29). Unlike TLR3 activation by poly(I:C), P3C application in vivo did not induce IFN production, rather only that of pro-inflammatory cytokines (24, 29, 30). Taken together, the direct antiviral effect of TLR2 activation is not the major factor for HBV control.
Previously, we also found that the TLR2 ligand application did not change the course of WHV infection when woodchucks were acutely infected with WHV and treated early with TLR2 ligands, consistent with the results in the HBV mouse models (Figure S3 in Supplementary Material).

The activation of TLR signaling leads to transient production of pro-inflammatory cytokines, such as secreted IL-6 and TNF-α in serum (17, 24). Early TLR2 activation may trigger host innate immunity and production of pro-inflammatory cytokines (Figure 1). The pro-inflammatory cytokines produced in the host contribute to viral inhibition and reduce HBV replication in the liver (16, 17). Unfortunately, direct evidence is not yet available whether early TLR2 activation could enhance cellular immunity to clear HBV from the liver. We assume that other mechanisms like TNF-induced target cell killing may play a role to reduce HBV positive hepatocytes over time in this setting (31). Future studies will be needed to identify the exact antiviral mechanisms.

Although the antiviral effect of these cytokines is limited, they play a pivotal role for recruiting immune cells into the liver. The ultimate HBV clearance may mainly depend on HBV-specific CD8+ T cells in the liver, similar to the findings for TLR3 activation with poly(I:C) (25). We previously showed that TLR2 activation may also modulate the immune functions
of intrahepatic liver sinusoidal endothelial cells (LSECs) (32). However, we further found that intrahepatic KCs retained the tolerizing activity after TLR2 activation and even increased the IL-10 production (33). Thus, the recruitment of immune cells into the liver, especially macrophages, may be essential to support T cells as effector cells against HBV (20). In this light, Huang described that iMATEs, which can attract activated CD8 T cells, are induced by intrahepatic application of TLR9 ligands (25).

Owing to the process of recruiting immune cells, a time lag is observed between TLR activation and HBV clearance in the liver (24). In the previous study, the application of poly(I:C) by HI led to transient production of type I IFN and induction of ISGs within hours. Although HBV replication decreased in the following days, the ultimate HBV clearance occurred only after CD8+ T cells were recruited in the dependence of CXCR3 into the liver. The peak of CD8+ cell infiltration into the liver was measured between days 20 and 30 after poly(I:C) application, which coincided with significant reduction of HBV loads (24). In the same line, TLR2 activation contributes to HBV control if the HI was performed 2 weeks later.

The fact that pretreatment of mice with TLR2 ligands led to enhanced specific T-cell responses and improved HBV control is consistent with the concept that the activation of innate immunity facilitates the initiation of adaptive immunity (34). Apparently, stimulation with TLR2 ligands gives a general activation of the host immune system and this enhanced activation status may be maintained for a while to respond to a possible invasion of pathogens. The immune activation is associated with the recruitment of various types of immune cells including macrophages, DCs, and T cells (24, 35). HBV HI into the liver with enriched immune cells triggered specific immune responses in a facilitated way. The recruitment of different immune cells into the liver occurs sequentially and requires a time period of more than 2 weeks for completion. Thus, TLR2 activation in the liver may accelerate HBV clearance through promoting the HBV-specific T-cell response but only if HBV infection is set after the completion of TLR2-mediated immune recruitment.

In the present study, we tested different ways to activate TLR2 by its ligands and measured the anti-HBV effects of these treatments. The routes and time points of the application of TLR2 ligands may determine the mode of immune activation in the hosts and the outcome of HBV control (24). Our results showed that the treatment of mice with P3C via SC application after the establishment of HBV replication was ineffective both for promoting adaptive immunity and viral suppression. The pre-activation of innate immunity by P3C injection significantly enhanced intrahepatic immunity and resulted in viral clearance in the mouse model of persistent HBV infection. These results presented here suggested the limitation and potential of TLR2-mediated immune activation to treat HBV infection and provide a guide for future studies.

**ETHICS STATEMENT**

All animal experiments were conducted in a BSL-2 laboratory facility in accordance with the Guide for the Care and Use of Laboratory Animals and were reviewed and approved by the Institutional Animal Care and Use Committee at Tongji Medical College, Huazhong University of Science and Technology, China (IACUC Number: 612).
AUTHOR CONTRIBUTIONS

ML and YX conceived and designed the study.YL, XH, JW, JL, MC, ZM, YL, SH, and QL performed the experiments and analyzed the data. YL, ML, and YX wrote the manuscript. EZ, XZ, JH, and DY provided materials and technical support and contributed to helpful discussions and review of the final manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors are grateful for the support from Deutsche Forschungsgemeinschaft and National Natural Science Foundation of China for funding the work of this study.

REFERENCES

1. Bertolotti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther (2010) 15(Suppl 3):15–24. doi:10.3851/IMP1620
2. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology (2015) 479(1–2):467–82. doi:10.1016/j.virology.2015.02.031
3. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol (2006) 1:23–61. doi:10.1146/annurev.pathol.1.110304.100230
4. Guidotti LG, Isogawa M, Chisari FV. Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol (2015) 36:61–6. doi:10.1016/j.coi.2015.06.016
5. Cuipe SM, Ribeiro RM, Perelson AS. Antibody responses during hepatitis B viral infection. PLoS Comput Biol (2014) 10(7):e1003730. doi:10.1371/journal.pcbi.1003730
6. Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol (2016) 64(1 Suppl):S60–70. doi:10.1016/j.jhep.2016.01.028
7. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 101(17):6669–74. doi:10.1073/pnas.0401771101
8. Cheng X, Xia Y, Serti E, Block PD, Chung M, Chayama K, et al. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology (2017) 66(6):1779–93. doi:10.1002/heap.29348
9. Chang I, Block TM, Guo JT. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res (2012) 96(3):405–13. doi:10.1016/j.antiviral.2012.10.001
10. Ma Z, Zhang E, Yang D, Lu M. Contribution of toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol (2015) 12(3):273–82. doi:10.1038/cmi.2014.112
11. Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol (2015) 204(1):1–20. doi:10.1007/s00430-014-0370-1
12. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140(6):805–20. doi:10.1016/j.cell.2010.01.022
13. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 101(9):3029–34. doi:10.1073/pnas.0401711101
14. Xu C, Lu Y, Zheng X, Feng X, Yang X, Timm J, et al. TLR2 expression in peripheral CD4+ T cells promotes Th17 response and is associated with disease aggravation of hepatitis B virus-related acute-on-chronic liver failure. Front Immunol (2017) 8:1609. doi:10.3389/fimmu.2017.01609
15. Feng D, Zhou L, Srivastava R, Aspoditis N, Velasco-Gonzalez C, Davila E. When toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood (2010) 116(18):3494–504. doi:10.1182/blood-2010-02-268169

FUNDING

ML was supported by grants from the Deutsche Forschungsgemeinschaft (RTG1949/1 and Transregio TRR60). YX was supported by grants from the National Natural Science Foundation of China (81201290) and the Fundamental Research Funds for the Central Universities (HUST: 2017KFXYJ052). DY was supported by grants from National Science and Technology Major Project for Infectious Diseases of China (2013ZX10002002).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.01495/full#supplementary-material.

16. Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, et al. Stimulation of the interleukin-1 receptor and toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther (2009) 14(6):797–808. doi:10.3851/IMP1294
17. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, et al. Role of toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol (2012) 57(3):522–8. doi:10.1016/j.jhep.2012.03.004
18. Zhang X, Meng Z, Qiu S, Xu Y, Yang D, Schlaak JF, et al. Lipopolysaccharide-induced innate immune responses in primary hepatocytes downregulates woodchuck hepatitis virus replication via interferon-independent pathways. Cell Microbiol (2009) 11(11):1624–37. doi:10.1111/j.1464-5822.2009.01353.x
19. Pang J, Zhang G, Lin Y, Xie Z, Liu H, Tang L, et al. Transforming growth factor beta-activated kinase 1 transcriptionally suppresses hepatitis B virus replication. Sci Rep (2017) 7:39901. doi:10.1038/srep39901
20. Ma Z, Liu J, Wu W, Zhang E, Zhang X, Li Q, et al. The IL-1R/TLR signaling pathway is essential for efficient CD8(+) T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol Immunol (2017) 14(12):997–1008. doi:10.1038/cmi.2017.43
21. Huang Z, Ge J, Pang J, Liu H, Chen J, Liao B, et al. Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Res (2015) 118:10–9. doi:10.1016/j.antiviral.2015.03.004
22. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology (2007) 45(1):102–10. doi:10.1002/hep.21482
23. Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov (2012) 7(7):597–611. doi:10.1517/17464411.2012.689281
24. Wu J, Huang S, Zhao X, Chen M, Lin Y, Xia Y, et al. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol (2014) 88(18):10421–31. doi:10.1128/JVI.00996-14
25. Huang LR, Wohlleber D, Reisinger F, Jenne CN, Cheng RL, Abdullah Z, et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol (2013) 14(6):574–83. doi:10.1038/ni.2573
26. Huang LR, Wu HL, Chen PJ, Chen DS. An immune competent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2006) 103(7):17862–7. doi:10.1073/pnas.0608578103
27. Kosinska AD, Pishraft-Sabet L, Wu W, Fang Z, Lenart M, Chen J, et al. Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models. Hepatology (2017) 66(1):69–83. doi:10.1002/hep.29155
28. Pan D, Lin Y, Wu W, Song J, Zhang E, Wu C, et al. Persistence of the recombinant genomes of woodchuck hepatitis virus in the mouse model. PLoS One (2015) 10(5):e0125658. doi:10.1371/journal.pone.0125658
29. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. *J Virol* (2005) 79(11):7269–72. doi:10.1128/JVI.79.11.7269-7272.2005

30. Real CI, Lu M, Liu J, Huang X, Tripper M, Hossbach M, et al. Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. *Sci Rep* (2016) 6:24865. doi:10.1038/srep24865

31. Wohlleber D, Kashkar H, Gartner K, Frings MK, Odenthal M, Hegenbarth S, et al. TNF-induced target cell killing by CTL activated through cross-presentation. *Cell Rep* (2012) 2(3):478–87. doi:10.1016/j.celrep.2012.08.001

32. Liu J, Jiang M, Ma Z, Dietze KK, Zelinsky G, Yang D, et al. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro. *J Immunol* (2013) 191(12):6178–90. doi:10.4049/jimmunol.1301262

33. Liu J, Yu Q, Wu W, Huang X, Broering R, Werner M, et al. TLR2 stimulation strengthens intrahepatic myeloid-derived cell-mediated T cell tolerance through inducing Kupffer cell expansion and IL-10 production. *J Immunol* (2018) 200(7):2341–51. doi:10.4049/jimmunol.1700540

34. Paul WE. Bridging innate and adaptive immunity. *Cell* (2011) 147(6):1212–5. doi:10.1016/j.cell.2011.11.036

35. Huang S, Zou S, Chen M, Gao X, Chen L, Yang X, et al. Local stimulation of liver sinusoidal endothelial cells with a NOD1 agonist activates T cells and suppresses hepatitis B virus replication in mice. *J Immunol* (2018) 200(9):3170–9. doi:10.4049/jimmunol.1700921

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.